Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Ironwood Pharmaceuticals stock

IRWD
US46333X1081
A0X789

Price

4.12
Today +/-
+0.09
Today %
+2.46 %
P

Ironwood Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Ironwood Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Ironwood Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Ironwood Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Ironwood Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Ironwood Pharmaceuticals Stock Price History

DateIronwood Pharmaceuticals Price
9/30/20244.12 undefined
9/27/20244.02 undefined
9/26/20244.06 undefined
9/25/20243.93 undefined
9/24/20244.02 undefined
9/23/20244.08 undefined
9/20/20244.30 undefined
9/19/20244.51 undefined
9/18/20244.52 undefined
9/17/20244.48 undefined
9/16/20244.47 undefined
9/13/20244.57 undefined
9/12/20244.53 undefined
9/11/20244.35 undefined
9/10/20244.08 undefined
9/9/20243.98 undefined
9/6/20244.51 undefined
9/5/20244.66 undefined
9/4/20244.96 undefined
9/3/20244.98 undefined

Ironwood Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ironwood Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ironwood Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ironwood Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ironwood Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ironwood Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ironwood Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ironwood Pharmaceuticals’s growth potential.

Ironwood Pharmaceuticals Revenue, EBIT and net profit per share

DateIronwood Pharmaceuticals RevenueIronwood Pharmaceuticals EBITIronwood Pharmaceuticals Net Income
2029e726.24 M undefined0 undefined276.17 M undefined
2028e734.4 M undefined345.27 M undefined302.24 M undefined
2027e707.2 M undefined364.72 M undefined296.54 M undefined
2026e423.5 M undefined238.53 M undefined116.5 M undefined
2025e373.49 M undefined153.63 M undefined70.88 M undefined
2024e363.32 M undefined126.5 M undefined39.1 M undefined
2023442.74 M undefined168.34 M undefined-1 B undefined
2022410.6 M undefined250.34 M undefined175.07 M undefined
2021413.75 M undefined232.11 M undefined528.45 M undefined
2020389.5 M undefined156.5 M undefined106.2 M undefined
2019428.4 M undefined116.3 M undefined21.5 M undefined
2018346.6 M undefined13.9 M undefined-282.4 M undefined
2017298.3 M undefined-15.1 M undefined-116.9 M undefined
2016274 M undefined-51.5 M undefined-81.7 M undefined
2015149.6 M undefined-84.5 M undefined-142.7 M undefined
201476.4 M undefined-169.4 M undefined-189.6 M undefined
201322.9 M undefined-252 M undefined-272.8 M undefined
2012150.2 M undefined-72.8 M undefined-72.6 M undefined
201165.9 M undefined-66.1 M undefined-64.9 M undefined
201043.9 M undefined-60.8 M undefined-53 M undefined
200934.3 M undefined-60.8 M undefined-71.2 M undefined
200818.4 M undefined-48.3 M undefined-53.9 M undefined
20074.6 M undefined-54.7 M undefined-52.8 M undefined
20060 undefined-36.7 M undefined-37.2 M undefined

Ironwood Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
04183443651502276149274298346428389413410442363373423707734726
--350.0088.8926.4751.16130.77-85.33245.4596.0583.898.7616.1123.70-9.116.17-0.737.80-17.872.7513.4067.143.82-1.09
-----100.0099.3368.1865.79100.0099.2793.6290.4694.3999.23100.00100.00-------
000006514915501492722793134043864134100000000
-36-54-48-60-60-66-72-252-169-84-51-15131161562322501681261532383643450
--1,350.00-266.67-176.47-139.53-101.54-48.00-1,145.45-222.37-56.38-18.61-5.033.7627.1040.1056.1760.9838.0134.7141.0256.2651.4947.00-
-37-52-53-71-53-64-72-272-189-142-81-116-28221106528175-1,0023970116296302276
-40.541.9233.96-25.3520.7512.50277.78-30.51-24.87-42.9643.21143.10-107.45404.76398.11-66.86-672.57-103.8979.4965.71155.172.03-8.61
6.46.76.97.189.799.9106.4115.9136.8142.2144.9149152.6156160.7164.42186.31155.44000000
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Ironwood Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Ironwood Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (k)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
20072008200920102011201220132014201520162017201820192020202120222023
                                 
91.989.8122.3248164168.2197.6248.3439.4305.2221.4173.2177362.6620.13656.292.15
25.54.85.22.90.71.53.225.854.564.982.281117.2122.4114.04115.46129.12
00000000000000000
000006.722.1501.10.700.60000
1.711.248.12.986.29.26.397.312.41210.911.058.9712.01
119.1105.8131.5259167.6184.4229.1288.3500.2380.2311.6266.6306.8495.9745.23780.63233.29
4.124.621.834.433.637.537.429.821.120.517.317.330.225.522.9320.3118.17
00000000000000000
00000000000032.623.42414.590
000000000166.1159.9000003.68
0000000008008008008000000
12.689.27.97.87.912.511.297.8142.2116.147.632.314.5334.78284.99215.93
16.732.63142.341.445.449.941118.9329.6294.165.795.963.4381.7319.89237.79
0.140.140.160.30.210.230.280.330.620.710.610.330.40.561.131.10.47
                                 
223.8273.4298.40.10.10.10.10.10.10.10.20.20.20.20.160.150.16
00.010.010.530.540.650.821.061.211.261.321.391.481.531.541.351.36
-189.5-243.4-314.6-367.5-432.4-505-777.8-967.4-1,110.1-1,191.8-1,308.8-1,591.1-1,572.2-1,466.1-937.61-696.38-1,698.62
00000000-0.10-0.100000-3.03
00000000000000000
38.937.6-3.2159.6109.8144.138.288.695.166.79.8-196.3-93.262.6605.91652.38-346.3
5.63.74.84.36.421.710.29.88.617.71618.15.50.70.940.487.83
7.51416.717.118.126.821.926.227.545.245.653.534.631.542.5925.0267.47
15.81833.942.840.36.17.912.212.7220.40.30.901.320.021.24
00000000000000000
11.11.10.20.20.31.112.427.66.24.147.600116.860199.56
29.936.856.564.46554.941.160.676.491.166.1119.54132.2161.725.53276.1
21.10.90.40.40.3177.8160.7353.9366.6396.1366.3408430.3337.33396.25498.31
00000000000000000
58.657.5105.17733.630.621.919.593.6185.4133.742.647.134.221.9926.3742.96
60.658.610677.43430.9199.7180.2447.5552529.8408.9455.1464.5359.32422.62541.27
90.595.4162.5141.89985.8240.8240.8523.9643.1595.9528.4496.1496.7521.02448.14817.37
0.130.130.160.30.210.230.280.330.620.710.610.330.40.561.131.10.47
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Ironwood Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Ironwood Pharmaceuticals's financial health and stability.

Assets

Ironwood Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Ironwood Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Ironwood Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Ironwood Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200620072008200920102011201220132014201520162017201820192020202120222023
-37-53-55-73-51-64-72-272-189-142-81-116-28221106528175-1,031
11246101111121111141453111
000000000000000-3336572
2452058-21-34-27-35-30-38-5-237-100017211
000.010.010.010.030.040.040.080.090.080.060.230.110.090.070.061.16
00000001819222420181777513
000000000000001349
-33-6-25-3-67-75-69-273-155-106-25-100-7010168261273183
-2-2-21-3-17-9-14-9-3-4-104-4-8-7-100-1,026
-5-27-1517-21311530-101-56-9-17715188-11-100-1,026
-2-25621-19512444-91-53-5-7315597-40000
000000000000000000
-10-10-200174-2218-288-11600-120300
7550494020538914721385242632-818-4-1166
80504841203389313210303-41930-118-4-237277
7001000-7000-150-9000-29
000000000000000000
4116856-774349-61-1187-2077048-118525736-565
-36.3-9.5-47-6.9-85.1-84.9-83.6-283-159.1-110.9-130.1-105-79.53.5167261.63273.63-842.89
000000000000000000

Ironwood Pharmaceuticals stock margins

The Ironwood Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ironwood Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ironwood Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ironwood Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Ironwood Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ironwood Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ironwood Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ironwood Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ironwood Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ironwood Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ironwood Pharmaceuticals Margin History

Ironwood Pharmaceuticals Gross marginIronwood Pharmaceuticals Profit marginIronwood Pharmaceuticals EBIT marginIronwood Pharmaceuticals Profit margin
2029e100 %0 %38.03 %
2028e100 %47.01 %41.16 %
2027e100 %51.57 %41.93 %
2026e100 %56.32 %27.51 %
2025e100 %41.13 %18.98 %
2024e100 %34.82 %10.76 %
2023100 %38.02 %-226.37 %
2022100 %60.97 %42.64 %
2021100 %56.1 %127.72 %
202099.2 %40.18 %27.27 %
201994.42 %27.15 %5.02 %
201890.57 %4.01 %-81.48 %
201793.6 %-5.06 %-39.19 %
201699.31 %-18.8 %-29.82 %
201599.93 %-56.48 %-95.39 %
201466.62 %-221.73 %-248.17 %
201368.56 %-1,100.44 %-1,191.27 %
201299.4 %-48.47 %-48.34 %
2011100 %-100.3 %-98.48 %
2010100 %-138.5 %-120.73 %
2009100 %-177.26 %-207.58 %
2008100 %-262.5 %-292.93 %
2007100 %-1,189.13 %-1,147.83 %
2006100 %0 %0 %

Ironwood Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Ironwood Pharmaceuticals earnings per share therefore indicates how much revenue Ironwood Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ironwood Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ironwood Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ironwood Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ironwood Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ironwood Pharmaceuticals Revenue, EBIT and net profit per share

DateIronwood Pharmaceuticals Sales per ShareIronwood Pharmaceuticals EBIT per shareIronwood Pharmaceuticals Earnings per Share
2029e4.55 undefined0 undefined1.73 undefined
2028e4.6 undefined0 undefined1.89 undefined
2027e4.43 undefined0 undefined1.86 undefined
2026e2.65 undefined0 undefined0.73 undefined
2025e2.34 undefined0 undefined0.44 undefined
2024e2.27 undefined0 undefined0.24 undefined
20232.85 undefined1.08 undefined-6.45 undefined
20222.2 undefined1.34 undefined0.94 undefined
20212.52 undefined1.41 undefined3.21 undefined
20202.42 undefined0.97 undefined0.66 undefined
20192.75 undefined0.75 undefined0.14 undefined
20182.27 undefined0.09 undefined-1.85 undefined
20172 undefined-0.1 undefined-0.78 undefined
20161.89 undefined-0.36 undefined-0.56 undefined
20151.05 undefined-0.59 undefined-1 undefined
20140.56 undefined-1.24 undefined-1.39 undefined
20130.2 undefined-2.17 undefined-2.35 undefined
20121.41 undefined-0.68 undefined-0.68 undefined
20110.66 undefined-0.66 undefined-0.65 undefined
20100.49 undefined-0.68 undefined-0.59 undefined
20094.83 undefined-8.56 undefined-10.03 undefined
20082.67 undefined-7 undefined-7.81 undefined
20070.69 undefined-8.16 undefined-7.88 undefined
20060 undefined-5.73 undefined-5.81 undefined

Ironwood Pharmaceuticals business model

Ironwood Pharmaceuticals Inc is a biopharmaceutical company that was founded in 1998. It is headquartered in Cambridge, Massachusetts in the USA. The company develops and markets drugs for the treatment of gastrointestinal diseases and other serious conditions. Ironwood Pharmaceuticals has a diversified product portfolio and works with other pharmaceutical companies to develop innovative therapies. The company's business model is based on the discovery, development, and marketing of drugs for the treatment of gastrointestinal diseases and other serious conditions. Ironwood Pharmaceuticals focuses on the development of new proprietary molecules tailored to specific patient needs. By collaborating with other pharmaceutical companies, Ironwood Pharmaceuticals aims to shorten development time and achieve higher efficiency in the value chain. The different divisions of Ironwood Pharmaceuticals specialize in the development of drugs for various diseases. The company has a strong expertise in the development of drugs for the treatment of gastrointestinal diseases such as irritable bowel syndrome and hyperactive bladder syndrome. Ironwood Pharmaceuticals has also contributed to the research of new therapies for serious conditions such as volvulus and adrenocortical carcinoma. The company has launched several products. The most significant drug of Ironwood Pharmaceuticals is Linzess, a medication for the treatment of chronic constipation and irritable bowel syndrome. The drug increases fluid content in the intestines, facilitating bowel movements. Linzess has proven to be very successful for the company and is available on the market in the USA and other countries. Another important product of Ironwood Pharmaceuticals is Amitiza, a medication for the treatment of chronic constipation in women. The drug increases fluid content in the intestines and stimulates bowel movements. Amitiza has also successfully reached the Japanese market and is available in several countries. Ironwood Pharmaceuticals has also achieved success in other areas of drug development. The company has partnered with Allergan Inc. for the development of drugs against hyperactive bladder syndrome and irritable bowel syndrome. This collaboration has led to new innovative therapies. In general, Ironwood Pharmaceuticals values the needs of patients and works with patient organizations to advance the development of drugs for the treatment of gastrointestinal diseases and other serious conditions. The company is committed to being increasingly concerned about the well-being of patients and the protection of their health. In summary, Ironwood Pharmaceuticals Inc is a leading biopharmaceutical company specializing in the discovery, development, and marketing of drugs for the treatment of gastrointestinal diseases and other serious conditions. With a broad portfolio of innovative therapies and partnerships with other pharmaceutical companies, Ironwood Pharmaceuticals contributes to improving the lives of patients worldwide. Ironwood Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Ironwood Pharmaceuticals SWOT Analysis

Strengths

Ironwood Pharmaceuticals Inc possesses several strengths that contribute to its success in the market. These strengths include:

  • Strong product portfolio: Ironwood Pharmaceuticals Inc boasts a diverse range of innovative and high-quality pharmaceutical products.
  • Strong market presence: The company has established a solid reputation and brand recognition within the pharmaceutical industry.
  • Effective research and development capabilities: Ironwood Pharmaceuticals Inc invests significantly in research and development to continuously improve its product offerings and stay ahead of the competition.
  • Experienced management team: The company is led by a team of experienced professionals who possess deep industry knowledge and expertise.

Weaknesses

However, Ironwood Pharmaceuticals Inc also faces certain weaknesses that may hinder its growth and performance in the market, including:

  • Dependence on a limited number of products: The company relies heavily on a limited number of flagship products, which may expose it to substantial risks if these products face challenges.
  • High competition: The pharmaceutical industry is highly competitive, making it challenging for Ironwood Pharmaceuticals Inc to maintain market share and pricing power.
  • Regulatory challenges: The complex and ever-evolving regulatory environment poses a potential hurdle for the company in terms of gaining necessary approvals and ensuring compliance.
  • Reliance on external suppliers: Ironwood Pharmaceuticals Inc may face supply chain disruptions and cost fluctuations due to its reliance on external suppliers for raw materials and components.

Opportunities

Ironwood Pharmaceuticals Inc can leverage a number of opportunities to further its growth and success, including:

  • Global expansion: The company can explore new markets and expand its geographical presence to capitalize on growing demand for pharmaceutical products in emerging economies.
  • Strategic partnerships and collaborations: Ironwood Pharmaceuticals Inc can enter into strategic partnerships and collaborations with other companies to drive innovation, access new markets, and share resources.
  • Technological advancements: The rapid advancements in technology present an opportunity for the company to develop and deliver more efficient and effective pharmaceutical products.
  • Increasing focus on healthcare and wellness: The growing global focus on healthcare and wellness provides Ironwood Pharmaceuticals Inc with an opportunity to develop products that cater to this expanding market.

Threats

Ironwood Pharmaceuticals Inc should remain aware of certain threats that could impact its business and industry, including:

  • Patent expirations: The expiration of patents for key products can lead to increased competition from generic alternatives and potentially reduce the company's market share and revenue.
  • Regulatory challenges: Changes in regulations related to pharmaceuticals and healthcare can pose challenges in terms of compliance and the ability to bring new products to market.
  • Economic volatility: Economic downturns and financial instability can impact consumer spending on pharmaceutical products, potentially affecting Ironwood Pharmaceuticals Inc's sales and profitability.
  • New entrants and disruptive technologies: The entry of new competitors and disruptive technologies in the pharmaceutical industry may disrupt existing market dynamics and pose a threat to the company's market position.

Ironwood Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Ironwood Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Ironwood Pharmaceuticals shares outstanding

The number of shares was Ironwood Pharmaceuticals in 2023 — This indicates how many shares 155.435 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ironwood Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ironwood Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ironwood Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ironwood Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.16 0  (-100 %)2024 Q2
3/31/20240.19 -0.02  (-110.27 %)2024 Q1
12/31/20230.21 -0.01  (-104.77 %)2023 Q4
9/30/20230.16 0.09  (-44 %)2023 Q3
6/30/20230.25 0.31  (23.21 %)2023 Q2
3/31/20230.25 0.25  (1.05 %)2023 Q1
12/31/20220.28 0.27  (-1.96 %)2022 Q4
9/30/20220.27 0.28  (3.59 %)2022 Q3
6/30/20220.3 0.21  (-30.21 %)2022 Q2
3/31/20220.26 0.21  (-19.26 %)2022 Q1
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Ironwood Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

69/ 100

🌱 Environment

36

👫 Social

99

🏛️ Governance

73

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees52
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Ironwood Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
7.21929 % State Street Global Advisors (US)11,532,088-464,77712/31/2023
4.50656 % Pacer Advisors, Inc.7,198,7787,198,7783/31/2024
4.24571 % LSV Asset Management6,782,101-382,10812/31/2023
4.12915 % Renaissance Technologies LLC6,595,898796,00012/31/2023
3.56830 % Armistice Capital LLC5,700,0002,244,00012/31/2023
2.64466 % Victory Capital Management Inc.4,224,583-182,14912/31/2023
2.50407 % Credit Suisse International4,000,000-228,25912/31/2023
2.32217 % Brown Capital Management, LLC3,709,431-10,36512/31/2023
14.42930 % BlackRock Institutional Trust Company, N.A.23,049,358829,93312/31/2023
10.26042 % Sarissa Capital Management, L.P.16,390,000012/31/2023
1
2
3
4
5
...
10

Ironwood Pharmaceuticals Executives and Management Board

Mr. Thomas Mccourt65
Ironwood Pharmaceuticals Chief Executive Officer, Director (since 2009)
Compensation 7.89 M
Dr. Michael Shetzline64
Ironwood Pharmaceuticals Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Compensation 2.92 M
Mr. John Minardo48
Ironwood Pharmaceuticals Senior Vice President, Chief Legal Officer, Secretary
Compensation 2.41 M
Mr. Sravan Emany45
Ironwood Pharmaceuticals Chief Financial Officer, Senior Vice President
Compensation 712,362
Ms. Julie Mchugh58
Ironwood Pharmaceuticals Independent Chairman of the Board
Compensation 337,027
1
2
3

Most common questions regarding Ironwood Pharmaceuticals

What values and corporate philosophy does Ironwood Pharmaceuticals represent?

Ironwood Pharmaceuticals Inc represents a strong dedication to improving the lives of patients through innovative medicines. Their corporate philosophy is centered around delivering breakthrough treatments and therapies that address unmet medical needs. With a focus on gastrointestinal diseases such as irritable bowel syndrome with constipation (IBS-C) and gastrointestinal (GI) disorders, Ironwood Pharmaceuticals aims to provide effective solutions for patients worldwide. Their commitment to scientific excellence, collaboration, and patient advocacy drives their pursuit of transformative healthcare solutions. Ironwood Pharmaceuticals Inc is committed to making a positive impact within the pharmaceutical industry by advancing patient care and wellbeing.

In which countries and regions is Ironwood Pharmaceuticals primarily present?

Ironwood Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Ironwood Pharmaceuticals achieved?

Ironwood Pharmaceuticals Inc has achieved significant milestones since its inception. Notably, the company successfully developed and gained regulatory approval for its flagship drug, LINZESS® (linaclotide), which is used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood Pharmaceuticals Inc also formed a strategic collaboration with Allergan plc (now part of AbbVie Inc) to co-develop and co-commercialize LINZESS®. Moreover, the company advanced its pipeline with the development of potential treatments for various gastrointestinal and renal disorders. Ironwood Pharmaceuticals Inc's commitment to innovation and its focus on improving patients' lives solidify its position as a leading pharmaceutical company in the market.

What is the history and background of the company Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals Inc is a leading biotechnology company specializing in the development and commercialization of innovative medicines. Founded in 1998, Ironwood has since focused on advancing treatments for gastrointestinal diseases and fibrotic conditions. With a strong dedication to research and development, the company has successfully brought several approved drugs to market. Ironwood Pharmaceuticals Inc has established itself as a key player in the pharmaceutical industry, continuously striving to improve patients' lives. Through its commitment to scientific excellence and breakthrough therapies, Ironwood Pharmaceuticals Inc has positioned itself as a trusted name in the healthcare sector.

Who are the main competitors of Ironwood Pharmaceuticals in the market?

The main competitors of Ironwood Pharmaceuticals Inc in the market include Allergan plc, AstraZeneca plc, Pfizer Inc, and Takeda Pharmaceutical Company Limited.

In which industries is Ironwood Pharmaceuticals primarily active?

Ironwood Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Ironwood Pharmaceuticals?

The business model of Ironwood Pharmaceuticals Inc revolves around developing and commercializing innovative medicines for patients with gastrointestinal (GI) diseases. The company focuses on discovering, developing, and marketing medicines for indications like irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood Pharmaceuticals Inc leverages its expertise in the GI field to identify and advance potential therapies that address significant unmet needs in patient care. By prioritizing research and development, the company aims to improve the lives of individuals suffering from GI disorders and enhance their overall quality of life.

What is the P/E ratio of Ironwood Pharmaceuticals 2024?

The Ironwood Pharmaceuticals P/E ratio is 16.38.

What is the P/S ratio of Ironwood Pharmaceuticals 2024?

The Ironwood Pharmaceuticals P/S ratio is 1.76.

What is the AlleAktien quality score of Ironwood Pharmaceuticals?

The AlleAktien quality score for Ironwood Pharmaceuticals is 4/10.

What is the revenue of Ironwood Pharmaceuticals 2024?

The expected Ironwood Pharmaceuticals revenue is 363.32 M USD.

How high is the profit of Ironwood Pharmaceuticals 2024?

The expected Ironwood Pharmaceuticals profit is 39.1 M USD.

What is the business model of Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Inc is a biopharmaceutical company based in Cambridge, Massachusetts, that focuses on the research, development, and commercialization of innovative drugs for the treatment of serious diseases. The business model of Ironwood is based on the invention and commercialization of new drugs to improve the health and quality of life of patients. The company specializes in the development of therapeutics in the fields of gastroenterology, hepatology, oncology, and neuroscience. An important segment of Ironwood's business model is partnerships with other companies. Ironwood collaborates with numerous partners and hospitals to optimize the research and development of therapeutics. For example, Ironwood works with the Canadian company Allergan to market the gastrointestinal motility agent Linzess. Ironwood also has its own sales and marketing organization that focuses on promoting and marketing its products. The company aims to bring its products to the global market and maintain its leading position in the industry. One of Ironwood's leading products is Linzess, the first and only prescription medication for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C) in adults. Linzess aims to alleviate the symptoms of these conditions by increasing intestinal motility and facilitating bowel movements. Another important product of Ironwood is Zurampic, a medication for the treatment of gout in adults in combination with a xanthine oxidase inhibitor. Zurampic helps reduce uric acid in the body by increasing its excretion through the kidneys. Ironwood also has products in the pipeline that are in different stages of clinical development. These include IW-3718 for the treatment of reflux diseases and Olinciguat for the treatment of cystic fibrosis-associated respiratory complications. Overall, Ironwood has successfully built a business model specializing in the discovery and development of new drugs, with a focus on gastroenterology, hepatology, oncology, and neuroscience. The company works closely with partners and hospitals to optimize the research and development of therapeutics and market its products worldwide. With leading products like Linzess and Zurampic, along with promising products in the pipeline, Ironwood remains an important player in the industry.

What is the Ironwood Pharmaceuticals dividend?

Ironwood Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Ironwood Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Ironwood Pharmaceuticals or the company does not pay out a dividend.

What is the Ironwood Pharmaceuticals ISIN?

The ISIN of Ironwood Pharmaceuticals is US46333X1081.

What is the Ironwood Pharmaceuticals WKN?

The WKN of Ironwood Pharmaceuticals is A0X789.

What is the Ironwood Pharmaceuticals ticker?

The ticker of Ironwood Pharmaceuticals is IRWD.

How much dividend does Ironwood Pharmaceuticals pay?

Over the past 12 months, Ironwood Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ironwood Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Ironwood Pharmaceuticals?

The current dividend yield of Ironwood Pharmaceuticals is .

When does Ironwood Pharmaceuticals pay dividends?

Ironwood Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Ironwood Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ironwood Pharmaceuticals located?

Ironwood Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ironwood Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ironwood Pharmaceuticals from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Ironwood Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Ironwood Pharmaceuticals in the year 2023?

In the year 2023, Ironwood Pharmaceuticals distributed 0 USD as dividends.

In which currency does Ironwood Pharmaceuticals pay out the dividend?

The dividends of Ironwood Pharmaceuticals are distributed in USD.

All fundamentals about Ironwood Pharmaceuticals

Our stock analysis for Ironwood Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ironwood Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.